Global science and technology innovator, Danaher Corporation, has announced its definitive agreement to acquire Abcam plc, a leading global supplier of protein consumables. The acquisition will see Danaher acquire all outstanding shares of Abcam for $24.00 per share in cash, with a total enterprise value of approximately $5.7 billion including assumed debt.
Abcam, founded in 1998 and headquartered in Cambridge, UK, is known for providing the scientific community with highly validated antibodies, reagents, biomarkers, and assays crucial for drug discovery, life sciences research, and diagnostics. It serves around 750,000 researchers globally.
The acquisition aligns with Danaher’s strategy to aid drug discovery and accelerate the mapping of complex diseases. Abcam is set to function as a standalone operating company and brand within Danaher’s Life Sciences segment.
The transaction is expected to be completed in mid-2024, subject to customary conditions, regulatory approvals, and Abcam shareholder approval. Danaher plans to fund the acquisition using cash on hand and proceeds from the issuance of commercial paper.
Both companies express excitement about the merger and see it as a way to further their respective missions in the field of life sciences and healthcare.
